← Leaderboards
Bret Daniel Ulery
University Of Missouri-Columbia
$767,856
Attributed
$1,065,535
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $470.2K · FY2019–25$500K$375K$250K$125K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,065,535 · 3
By mechanism
R21$595,358 · 1
R35$384,896 · 1
U42$85,281 · 1
Top collaborators
- Mark A. Daniels2 shared
Most similar at University Of Missouri-Columbia
Same institution · by research overlap
- Raghuraman Kannan$5,372,272
- Aaron Ericsson$1,907,086
- Ov D Slayden$15,947,398
- Mark A. Daniels$297,679
Others in their field
Other Emerging Leaders on “Devices”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Mark Marino · Venturewell$49,647,567
- Stuart Hellyar Hellyar$34,175,230
- Pamela Winer Goldberg · Medical Device Innovation Consortium$31,780,000
- Hanjoon Ryu$28,519,898
Research focus
DevicesComplexIn VivoPeptide DrugSpecificityPerformanceDosageClinical ApplicationIn VitroMicellesPublishingResponseTechnologyTissuesCellsHarvestDesignPeptidesAutoimmune DiseasesHigh RiskBiocompatible MaterialsAntineoplastic AgentsCancer EtiologyCancer Relapse
Grant awards (4)
Maximizing Peptide Therapeutic Delivery Through Biomodulatory Materials Design$384,896
R35 · FY2025 · GM · contact PI
Novel pH-Sensitive Particles for Noninvasive Upper GI Tract Microbiota Sampling$85,281
U42 · FY2025 · OD · contact PI
Aptamer-Modified POSH Inhibitor Micelles as a Novel Leukemia Treatment Modality$297,345
R21 · FY2020 · EB · contact PI
Aptamer-Modified POSH Inhibitor Micelles as a Novel Leukemia Treatment Modality$298,013
R21 · FY2019 · EB · contact PI